

FIG. 1




FIG. 2


Comparison of Hinge/Spacers for β CG-ala-conjugates

FIG. 3




FIG. 4




FIG. 5




FIG. 6




Figure 7

Timeline in vivo to test efficacy of Phor21- β CG-ala,
Phor18- β CG-ala, Phor21, Phor18 and ML- β CG-ala inactive
peptide




Figure 8

Figure 8A

I) Tumor Volume During Efficacy Study

MDA-MB-435S.luc Xenografts




Figure 8B

MDA-MB-435S.luc Xenografts






FIG. 8C



II) Tumor Volume, Weight, Tumor cell Numbers, Tumor Conditions and Body weights at Necropsy.

Necropsy Tumor Volumes



Necropsy Tumor weights




FIG. 8F




FIG. 8G




FIG. 8H




FIG. 8I





Figure 8

Figure 8J

323033 Phor21- β -CG-ala337476 Phor18- β CG-ala337481 D-ala-Phor21- β CG-ala

338982 Phor21

338983 Phor18

338984 (KKKFAFA)₃- β CG-ala

Tumor Volume Efficacy Study E 4

FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 9E




FIG. 9F




FIG. 9G





FIG. 9H



p < 0.01 compared to baseline

Efficacy Study - LHRH-conjugated Cytolytic Peptides

FIG. 10A




FIG. 10B

Changes in Tumor Weights Compared to Baseline




FIG. 10C






FIG. 10D



*p<0.04 compared to 33 2 mg/kg

FIG. 10E



323033 = Phor21- β CG-ala

338611 = D-ala-Phor21-LHRH

338612 = Phor18-ASAAS-LHRH

338613 = Phor18 LHRH

339347 = Phor18 Lupron

339385 = D-ala-Phor18-LHRH

FIG. 11




FIG. 12

Toxicity of Phor21-conjugates to CHO and TM4 cells
in comparison to MDA-MB-435S.luc cells




Figure 13A




Figure 13B




Figure 14

Figure 14A




Figure 14B




Figure 14C




Figure 14D




Figure 14E




Figure 14F




Figure 15

Figure 15A




Figure 15B




Figure 15

Figure 15C




Figure 15D




Figure 15

Figure 15E




Figure 16

Figure 16A




Figure 16B




Figure 17

Figure 17A





Figure 17B



Treatment group:

1. Control antibodies (10 mice)
2. EP-100 (10 mice), 0.2 mg/kg
3. α-PDL-1 (10 mice), 10 mg/kg
4. EP-100 + α-PDL-1 (10 mice)

Figure 17

Figure 17C





Figure 17

Figure 17D



TGI [%]		
EP-100 (N=10)	αPDL1 (N=20)	αPDL1+EP -100 (N=20)
60.9	60.9	82.7

33/43

Fig. 17E

Ascites [%]		
EP-100 (N=10)	αPDL1 (N=20)	αPDL1+EP-100 (N=20)
35.5	15	58.4




Figure 18

Figure 18A

Tumor




Figure 18

Figure 18A (Cont.)

Tumor




Figure 18

Figure 18A (Cont.)




Figure 18

Figure 18B

Ascites




Figure 18

Figure 18B (Cont.)

Ascites




Figure 19

Figure 19A




Figure 19

Figure 19B




Figure 19

Figure 19C




Figure 19D




Figure 20

Figure 20A




Figure 20B




Figure 20C




Fig. 21